ARCHIVES

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

This article is from The Cancer Letter archive.

Vol. 07 No. 21 | May 22, 1981

Download PDF Visit The Full Archive

Related Articles

Bioassay Backlog Reports show Increasing Number Of Equivocal Results; Is The Program A Failure?

September 2, 1977

NCI Evaluating PDQ Evaluation

September 1, 1989

FDA Staff Failed To Explain Approval Standards, Correct Misconceptions.

April 13, 2007

ACS Reports Breast Cancer Incidence At All Time High

January 23, 1987

NIH Begins Undiagnosed Diseases Program.

May 30, 2008

Clinical Education Program Phase Out Opposed By NCAB Committee

February 14, 1986